EUVIMEDEUVIMED entdecken
Crossref

Unveiling the sumatriptan dose-relief relationship

Clément Rigaut iD, Benoit Haut, Pierre Lambert, Jonathan Goole

European Journal of Clinical Pharmacology · 2026-08 · 82 (8)

DOI: 10.1007/s00228-026-04137-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 16.07.2026. Verfasst von Clément Rigaut und 3 weiteren Autor:innen. Beteiligte Einrichtung: TIPs (Transfers, Interfaces and Processes), Université libre de Bruxelles, Brussels, Belgium. clement.rigaut@ulb.be. Hauptthemen laut MEDLINE: Sumatriptan, Migraine Disorders, Models, Biological, Serotonin 5-HT1 Receptor Agonists. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Université Libre de Bruxelles.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This article aims to correlate the pharmacokinetic parameters of sumatriptan to the percentage of patients experiencing relief after two hours. METHODS: Using data from the literature, a two-compartment pharmacokinetic model is developed to compute the concentration of sumatriptan in the brain across various routes of administration and doses. This concentration is then correlated to its clinical effect. RESULTS: The maximum concentration of sumatriptan in the brain correlates linearly with the percentage of patients experiencing pain relief after two hours. Based on the evolution over time of the brain concentration, the action time can also be predicted for different route-dose combinations. CONCLUSION: The present correlation provides a relationship between the dose of sumatriptan and its effect for multiple routes of administration. The approach developed in this work could be adapted to other molecules to explore their dose-response relationships.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SumatriptanMigraine DisordersModels, BiologicalSerotonin 5-HT1 Receptor AgonistsHumansDose-Response Relationship, DrugBrain

Stichwörter der Autor:innen

ConcentrationMigrainePharmacokineticsResponseTriptan

Substanzen

SumatriptanSerotonin 5-HT1 Receptor Agonists

Autor:innen und Institutionen

  • TIPs (Transfers, Interfaces and Processes), Université libre de Bruxelles, Brussels, Belgium. clement.rigaut@ulb.be.
  • TIPs (Transfers, Interfaces and Processes), Université libre de Bruxelles, Brussels, Belgium.
  • Therapeutic Chemistry department, Université libre de Bruxelles, Brussels, Belgium.

ORCID-Profile: Clément Rigaut

Förderung

  • Université Libre de Bruxelles

Zitieren

APA

Rigaut, C., Haut, B., Lambert, P., & Goole, J. (2026). Unveiling the sumatriptan dose-relief relationship. European Journal of Clinical Pharmacology, 82(8). https://doi.org/10.1007/s00228-026-04137-0

Vancouver

Rigaut C, Haut B, Lambert P, Goole J. Unveiling the sumatriptan dose-relief relationship. European Journal of Clinical Pharmacology. 2026;82(8). doi:10.1007/s00228-026-04137-0

BibTeX
@article{Rigaut2026,
  author = {Rigaut, Clément and Haut, Benoit and Lambert, Pierre and Goole, Jonathan},
  title = {Unveiling the sumatriptan dose-relief relationship},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {8},
  doi = {10.1007/s00228-026-04137-0}
}
Kostenlos starten →